Physician profile
Lavan Harris
NPI 1326749631
$1,847.20
in general payments reported to CMS, 2019-2025
28 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $376 · 2024: $696 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $365.09 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $217.99 | 2024-2025 | |
| Glaxosmithkline, LLC. | $194.62 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $171.30 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Sumitomo Pharma America, INC. | $124.99 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals Lp | $124.56 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $104.61 | 2023-2025 | |
| Astellas Pharma US INC | $71.20 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $58.41 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.96 | 2024 | Camzyos, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $32.91 | 2023-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.09 | 2025 | Xifaxan |
| Cequr Corporation | $30.26 | 2025 | Cequr Simplicity |
| Exact Sciences Corporation | $29.36 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $25.65 | 2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $22.80 | 2025 | Symbravo |
| Daiichi Sankyo INC. | $22.32 | 2023 | Injectafer |
| Averitas Pharma INC. | $22.06 | 2025 | Qutenza |
| Inspire Medical Systems, INC. | $21.41 | 2025 | Inspire |
| Ferring Pharmaceuticals INC. | $18.92 | 2025 | Euflexxa |
| Depuy Synthes Sales INC. | $18.27 | 2024 | Orthovisc, Monovisc |
| Otsuka America Pharmaceutical, INC. | $17.70 | 2025 | Rexulti |
| Corcept Therapeutics | $16.60 | 2023 | Korlym |
| Teva Pharmaceuticals USA, INC. | $15.90 | 2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.75 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $14.09 | 2023 | Xarelto |
| Xeris Pharmaceuticals, INC. | $13.94 | 2023 | Gvoke Hypopen |
| Bioventus LLC | $13.44 | 2024 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lavan Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.